Status:
COMPLETED
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Lead Sponsor:
St. Jude Children's Research Hospital
Conditions:
Germ Cell Tumors
Hepatic Cancer
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE1
PHASE2
Brief Summary
Life-threatening thrombocytopenia (low platelet count) and neutropenia (low white blood count) remain the major dose-limiting toxicities following chemotherapy treatment for cancer. The only remedy fo...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of recurrent, refractory, or previously untreated malignant solid tumor or recurrent/refractory lymphoma for which Ifosfamide, Carboplatin, and Etoposide chemotherapy is the most appropriate treatment.
- Adequate liver and kidney function.
- Adequate performance status.
Exclusion
Key Trial Info
Start Date :
June 1 2000
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00187109
Start Date
June 1 2000
End Date
February 1 2007
Last Update
April 10 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105